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Abstract
Aims/hypothesis Diabetes is a worldwide epidemic linked with diverse diseases of the nervous system, including depres-
sion. A few studies suggested a connection between renin–angiotensin–aldosterone system blockers and reduced depres-
sive symptoms, although underlying mechanisms are unclear. Here we investigated the antidepressant effect and the
mechanisms of action of the angiotensin receptor 1 blocker (ARB) losartan in an experiential model of diabetes-
associated depression.
Methods Experimental diabetes was induced by streptozotocin in adult male Wistar rats. After 5 weeks of diabetes, rats were
treated for 2 weeks with a non-pressor oral dose of losartan (20 mg/kg). In protocol 1, cerebrovascular perfusion and glial
activation were evaluated by single-photon emission computed tomography–MRI and immunohistochemistry. In protocol 2,
behaviour studies were performed (forced swim test and open field test). Hippocampal proinflammatory response and brain-
derived neurotrophic factor (BDNF) signalling were also assessed.
Results Here, we show that diabetic rats exhibit depression-like behaviour, which can be therapeutically reversed by
losartan. This action of losartan occurs via changes in diabetes-induced neuroinflammatory responses rather than altered
cerebral perfusion. We also show that as a part of its protective effect losartan restores BDNF production in astrocytes
and facilitates BDNF–tropomyosin receptor kinase B–cAMP response element-binding protein signalling in the diabetic
brain.
Conclusions/interpretation We identified a novel effect of losartan in the nervous system that may be implemented to alleviate
symptoms of diabetes-associated depression. These findings explore a new therapeutic horizon for ARBs as possible antidepres-
sants and suggest that BDNF could be a target of future drug development in diabetes-induced complications.
Keywords Angiotensin receptor 1 blocker . Brain-derived neurotrophic factor . Depression . Neuroinflammation . Renin–
angiotensin–aldosterone system
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Abbreviations
ARB Angiotensin receptor 1 blocker
BAX BCL2-associated X protein
BCL2 B cell lymphoma 2
BDNF Brain-derived neurotrophic factor
CREB cAMP response element-binding protein
eNOS Endothelial nitric oxide synthase
ERK Extracellular signal-regulated kinase
FST Forced swim test
GFAP Glial fibrillary acidic protein
Iba1 Ionised calcium-binding adaptor molecule 1
ICAM-1 Intercellular adhesion molecule 1
[125I]CLINME 125I-labelled 6-chloro-2-(4′-iodophenyl)-
3-(N,N-methylethyl)imidazo[1,2-a]pyri-
dine-3-acetamide
JNK c-Jun N-terminal kinase
mBDNF Mature brain-derived neurotrophic factor
MAP Mean arterial pressure
MMP Matrix metalloproteinase
OFT Open field test
p75NTR Neurotrophin receptor p75
proBDNF Precursor brain-derived neurotrophic factor
RAAS Renin–angiotensin–aldosterone system
SPECT Single-photon emission computed
tomography
SUV Standardised uptake value
STZ Streptozotocin
[99mTc]HMPAO 99mTc-labelled hexamethylpropyleneamine
oxime
TPA Tissue plasminogen activator
TrkB Tropomyosin receptor kinase B
VOI Volume of interest
Introduction
Noncommunicable diseases represent a major challenge for
health systems, further augmented by the co-occurrence of
multiple chronic conditions. While both diabetes and depres-
sion present huge socioeconomic problems affecting millions
of people worldwide, the role of diabetes in increasing the risk
of depression is only beginning to emerge [1].
The link between the two diseases is unclear at present due
to lack of appropriate mechanistic insight. Depression causes
deterioration in carbohydrate metabolism and increases the
frequency of complications; it also impairs the quality of life
and reduces life expectancy [2]. In addition, the incidence of
depression is markedly increased in individuals with diabetes
[3]. Since diabetes is now widely recognised as a state of
chronic systemic inflammation [4], inflammatory actions
could represent a plausible mechanism through which diabe-
tes and depression interact [5]. However, there is insufficient
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experimental evidence to support this hypothesis and effective
therapies are lacking.
A clear association between depressive symptoms and re-
duced levels of the growth factor, brain-derived neurotrophic
factor (BDNF), has long been recognised [6]. Hippocampal
biopsies of individuals with major depression revealed lower
levels of BDNF and its receptor, tropomyosin receptor kinase
B (TrkB) [7]. Moreover, TrkB signalling has been implicated
in the action of antidepressants, even positioning this pathway
as a potential predictor for the efficacy of antidepressants [8].
BDNF is predominantly produced in the central nervous
system in the form of a precursor (proBDNF) from which
mature BDNF (mBDNF) is derived via proteolytic cleavage.
mBDNF induces axon growth and synaptic activity and facil-
itates cell survival through its receptor, TrkB. ProBDNF is
itself also biologically active, although it has an opposing func-
tion whereby it decreases synaptic activity and activates apo-
ptotic pathways via neurotrophin receptor p75 (p75NTR) [9].
Several in vitro and in vivo studies indicate that
neuroinflammatory processes, which are widely linked with
the development of depression, affect BDNF expression [10].
Notably, lipopolysaccharide or proinflammatory cytokine ad-
ministration has been demonstrated to remarkably reduce
mRNA and protein levels of BDNF in the brain [11, 12].
Renin–angiotensin–aldosterone system (RAAS) inhibitors
are currently one of the primary options in the treatment of
diabetes and related complications [13]. Recent findings from
a large cohort of individuals with type 1 diabetes showed that
RAAS-modifying medication was associated with a reduced
requirement for antidepressants [14]. Furthermore, treatment
with the angiotensin receptor 1 blocker (ARB) candesartan
significantly improved interpersonal sensitivity and depres-
sion scores of diabetic individuals [15].
A local RAAS, expressing all classical signalling path-
ways, also exists in the brain, where it regulates a wide variety
of biological functions including blood pressure, body tem-
perature, memory, behaviour and learning [16]. Clinical stud-
ies have confirmed that increased RAAS activity in the brain
is associated with the development of depression, Alzheimer’s
disease and Parkinson’s disease [17–19].
We hypothesised that blockade of RAAS activity by losartan,
a widely used treatment regimen in the clinic, may exert antide-
pressant effects in an experimental model of diabetes. Here we
investigated the importance of BDNF signalling in the inflam-
matory, survival and apoptotic processes of diabetes-associated
depression, and suggest novel targets for clinical therapy.
Methods
Animals All experiments were conducted in accordance with
guidelines of the Council on Animal Care of the National
Health Institution of Hungary (PEI/001/380-4/2013).
Adult, male Wistar rats (Crl:WI; Toxi-Coop, Budapest,
Hungary) were housed in temperature- and humidity-
controlled units (22 ± 2°C and 70 ± 10%, respectively) with
a 12 h light–dark cycle (lights on at 08:00 hours). Three rats
(randomly chosen from treatment groups) were housed per
cage and had free access to standard chow and tap water.
General anaesthesia was induced by inhalation of isoflurane
(3% vol./vol.) mixed with air (1 l/min) in an isoflurane
vaporiser (Eickemeyer Veterinary Equipment, Twickenham,
UK).
Induction of diabetes and experimental design We used
streptozotocin (STZ, 65 mg/kg i.p single injection; Sigma-
Aldrich, St Louis, MO, USA) to induce diabetes as this is
the most widely accepted model of diabetes-associated de-
pression. After 5 weeks of diabetes, rats were randomly divid-
ed into groups and treated daily for 2 weeks by oral gavage as
follows: (1) isotonic saline (NaCl 154 mmol/l) as vehicle (n =
5–7 in protocol 1, n = 8 in protocol 2) or (2) losartan (losartan
20 mg/day, dissolved in isotonic saline, n = 5 or 6 in protocol
1, n = 6 in protocol 2). Experimental protocols are summarised
in electronic supplementary material (ESM) Fig. 1.
In protocol 1 imaging studies were conducted at the end of
the treatment period. Under terminal anaesthesia, rats were
perfused with 4% wt/vol. paraformaldehyde. Brains were
post-fixed in a solution containing 4% wt/vol. paraformalde-
hyde and 10% sucrose at 4°C for 24 h and cryoprotected in
10% wt/vol. sucrose solution.
In protocol 2, behaviour studies and biochemical and mo-
lecular measurements were performed at the end of the treat-
ment period. Rats were killed, blood and brains were collected
and hippocampi dissected.
In both protocols, age-matched non-diabetic control rats
received a single equivalent volume of citrate buffer without
STZ and were treated with saline by oral gavage daily for
2 weeks at the same time as the diabetic rats (n = 4 or 5 in
protocol 1, n = 8 in protocol 2). No adverse events were re-
corded in any of the procedures.
Measurement of arterial blood pressure and metabolic vari-
ables Systolic and diastolic blood pressure was measured on
the tail vein using a CODA Standard monitor system (EMKA
Technologies, Paris, France). Mean arterial pressure (MAP)
was calculated. In line with the literature, we chose a treatment
protocol that avoided blood pressure changes but remained
effective in blocking angiotensin II receptor 1. The protocol
was successfully applied in several independent experiments
in our previous work, wherein changes in MAP never oc-
curred in normotensive Wistar rats following administration
of either streptozotocin or losartan (20 mg/kg for 2 weeks)
[20]. Blood glucose and fructosamine were photometrically
determined from sera on a Hitachi 912 photometric chemistry
analyser (Roche Hitachi, Basel, Switzerland).
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Behavioural tests All behavioural tests were conducted at
08:30 hours in a separated testing room under ~15 W light
intensity. Tests were video-recorded using a DCR-SX21E vid-
eo camera recorder (Sony, Tokyo, Japan) and later manually
analysed with the H77 computer-based event recorder.
Open field test An open field test (OFT) was used to determine
the general locomotor activity and exploratory behaviour of rats.
Rats were individually placed in the centre of a square arena
fenced by white, non-transparent plastic walls (100 cm ×
100 cm × 60 cm box) with a floor divided into 10 cm × 10 cm
squares. The rats were allowed to explore freely for 10 min. The
arena was cleaned with water between tests.
Forced swim test The classical Porsolt forced swim test (FST),
commonly used in translational research on depression, was
used to assess depression-like behaviour. This test is based on
repeated exposure to an inescapable swim, which is repeated
under the same test conditions after a 24 h interval. During the
second test, animals typically spend a longer time floating and
this is regarded as being the most sensitive sign of ‘behavioural
despair’. The re-exposure of an animal to the originally present-
ed adverse situation is intended to produce a state of learned
helplessness, a behavioural hallmark of depression [21].
In our study, rats were placed in a cylindrical container (height
60 cm, diameter 14 cm) filledwith tapwater (25 ± 1°C). The pre-
test period lasted for 15 min. The procedure was repeated 24 h
later for a 5 min test session. Rats were fully dried and cylinders
were filled up with fresh water after each test. The time rats spent
floating (nomovement except ones needed to keep the head over
the water), struggling (vigorous limbmovement, forelimbs break
the surface of water, attempting to climb up on the cylinder) and
swimming (coordinated movement with all four limbs, limbs are
under the water) was recorded.
Radiochemistry and in vivo imaging To assess cerebrovascu-
lar blood flow and microglia activation, single-photon emis-
sion computed tomography (SPECT)–MRI imaging was car-
ried out on anaesthetised rats. Before acquisition, an i.p. injec-
tion of 14 mg/kg potassium perchlorate (Sigma-Aldrich) was
given followed by i.v. administration of 9.35 ± 2.00 MBq of
125I- label led 6-chloro-2-(4 ′- iodophenyl)-3-(N ,N-
methyle thyl) imidazo[1,2-a]pyr idine-3-acetamide
([125I]CLINME) (Progressio, Budapest, Hungary) and,
30 min later, 135.86 ± 6.84 MBq of 99mTc-labelled
hexamethylpropyleneamine oxime ([99mTc]HMPAO) (Medi-
Radiopharma, Erd, Hungary). MRI acquisitions were per-
formed immediately following the [99mTc]HMPAO injection,
using a nanoScan 1 T MRI system (Mediso, Budapest,
Hungary). A T1-weighted GRE 3D sequence was used
(460 μm in-plane resolution, slice thickness 500 μm, TR/TE
12/2 ms, TD 20 μs and four excitations resulting in a 9.5 min
acquisition).
The SPECT–CT measurements were performed on a
NanoSPECT/CT PLUS machine (Mediso) and results were
quantified in units (0.33 mm, isovoxels) of radioactivity mea-
sured in MBq/ml. An atlas-based method (ventricles, cerebel-
lum, cortex, hippocampus, striatum, bulbus olfactorius and
one volume of interest [VOI] containing the whole brain)
was used to segment the brain during MRI measurements.
For [99mTc]HMPAO, the standardised uptake values
(SUVs) of each segmented brain area were reported. For
[125I]CLINME, the ratio of tissue activity to arterial blood
activity was determined in every VOI using an image-based
arterial blood activity concentration measurement. This value
was normalised to the same area’s [99mTc]HMPAO SUV as
perfusion compensation. Image analysis of 3D SPECT VOIs
was performed with VivoQuant 1.22 patch2 software
(InviCRO, Boston, MA, USA).
Fluorescence immunohistochemistry Free-floating brain sec-
tions (25 μm thick) were either subjected to heat-induced epi-
tope retrieval or simply blocked with 5–10% normal donkey
serum and incubated overnight at 4°C with the appropriate
mixture of primary antibodies. For visualisation, secondary
antibodies labelled with AlexaFluor 488, 647 or 594 were
used. Details of antibodies are listed in ESM Tables 1 and 2.
Images were captured with an Ni-E C2+ (Nikon, Tokyo,
Japan) confocal microscope and image processing was per-
formed using the NIKONNIS Elements Viewer 4.20 software
(Auroscience, Budapest, Hungary). Quantitative analysis was
carried out on three randomly selected fields of view within
the region of interest for each brain section on 3-3 anatomi-
cally defined coronal sections.
Western blot analysis All reagents for western blot were pur-
chased from Bio-Rad Laboratories (Hercules, CA, USA).
Hippocampal samples were electrophoretically resolved,
transferred and membranes were immunoblotted with specific
primary antibodies. Horseradish peroxidase-conjugated sec-
ondary antibodies were used for chemiluminescence detection
by Luminata Forte (Millipore Corporation, Billerica, MA,
USA). Details of antibodies are listed in ESM Tables 3 and 4.
Densitometric analysis of bands was performed using
Quantity One Analysis 4.6.6. software (Versadoc; Bio-Rad
Laboratories). After background subtraction, integrated opti-
cal densities of bands of interest were factored for Ponceau S
staining to correct for variations in total protein loading. Each
blot was normalised to an internal control so that bands on
separate blots could be compared.
Real-time quantitative RT-PCR RNA was extracted using the
Total RNA Mini Kit (Geneaid Biotech, New Taipei City,
Taiwan), reverse-transcribed by SuperScript III and the sam-
ples were diluted to 250 ng/μl (Life Technologies, Carlsbad,
CA, USA). Expression levels Il1a, Il6, Tnf, Bcl2, Bax and 18S
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mRNA were determined by LightCycler 480 (Roche
Diagnostics, Mannheim, Germany). Primer sequences are
listed in ESM Table 5.
Statistical analysis Data were analysed in a blinded-fashion in
behaviour tests and imaging experiments (SPECT-MRI and
immunohistochemistry). Other experiments were not per-
formed blind. Analysis was performed by one-way ANOVA
followed by Holm–Sidak’s post hoc test using GraphPad
Prism 6 software (GraphPad Software, San Diego, CA,
USA) for multiple comparisons. For non-parametrical data
the Kruskal–Wallis ANOVA on ranks followed by Dunn’s
post hoc test was calculated. Pearson correlation was evaluat-
ed to reveal any interdependence of blood glucose or body
weight and floating. Results are presented as means ± SD.
p < 0.05 was considered as significant.
Results
Losartan ameliorates depression-like behaviour in diabetic
rats In the OFT, both vehicle- and losartan-treated diabetic rats
performed fewer grid crossings, indicating that the general
physical condition of these rats was worse than that of the
non-diabetic control group (Fig. 1a). We investigated whether
diabetes is associated with depressive behaviour in this exper-
imental model. During the FST, floating time was longer in
vehicle-treated diabetic rats than in control rats, reflecting the
development of behavioural despair, a sign of depression-like
behaviour (Fig. 1b).
Treatment of diabetic rats with losartan decreased floating
time and, in parallel, increased the total time of mobility (Fig.
1b, c). When different movement variables were measured
separately, the time spent struggling (the most representative
movement pattern for active behaviour) was significantly in-
creased by losartan treatment (Fig. 1d–f). These results sug-
gest that losartan has a strong antidepressant effect. Since
losartan did not influence locomotor activity in the OFT, the
improved FST results can indeed be attributed to the antide-
pressant effect of losartan.
Diabetes led to decreased body weight gain and elevated
blood glucose and fructosamine levels, none of which was
improved by losartan (ESM Table 6). Neither body weight
(r = −0.2601; p = 0.5339) nor blood glucose (r = −0.03226;
p = 0.9396) influenced floating variables in diabetes.
Diabetic rats show decreased cerebral perfusion, which is not
altered by losartan Cerebral perfusion, reported to be altered
in experimental models of diabetes [22], was measured to
study the mechanisms through which losartan may exert its
actions on depressive behaviour. Since MAP remained unal-
tered in all groups (Fig. 2a), cerebral perfusion was studied
using [99mTc]HMPAO [23].
[99mTc]HMPAO uptake was reduced in diabetic rats in ev-
ery segmented brain region, indicating reduced cerebral per-
fusion. Losartan treatment did not change tracer uptake, sug-
gesting unaltered cerebral blood flow (Fig. 2b, c).
Intercellular adhesion molecule 1 (ICAM-1) is a widely
used marker of cerebrovascular activation [24]. Increased
ICAM-1 immunostaining was observed in diabetic rats vs
control rats and this increased level was not significantly re-
duced by losartan (Fig. 2d, e).
Endothelial nitric oxide synthase (eNOS) and endothelin-1
are bothmajor regulators of cerebral blood flow. Phosphorylated
eNOS (Ser1177; p-eNOS) levels did not differ between all
groups of rats (Fig. 2f). Endothelin-1 protein level was higher
Fig. 1 Losartan attenuates depressive behaviour of diabetic rats. OFTand
FST were performed on control (non-diabetic) rats, vehicle-treated dia-
betic rats (DM) and losartan-treated diabetic rats (DM+LOS). (a) In OFT,
locomotor activity is represented by number of grid crossings. (b–f) In
FST, floating reflects immobility (b), while time spent in active mobility
(c) is represented by struggling (d), swimming (e) and diving (f). Each
moving pattern is represented as percentage of time. Data are presented as
mean ± SD (n = 6–8/group). *p < 0.05, **p < 0.01 and ***p < 0.001 vs
control rats; †p < 0.05 vs DM
Diabetologia (2019) 62:1501–1513 1505
in the hippocampus of diabetic rats and was not lowered by
losartan treatment (Fig. 2g).
Losartan ameliorates diabetes-induced neuroinflammation
Next, we investigated whether altered glial responses may
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explain the antidepressant effects induced by losartan.
Activation of microglia, as assessed by translocator protein
ligand [125I]CLINME using SPECT imaging in vivo, was in-
creased in diabetic rats compared with control rats (Fig. 3a, b);
this increase was not altered by losartan treatment. A similar
pattern was observed in every segmented brain region (ven-
tricles, cerebellum, cerebral cortex, hippocampus, striatum
and bulbus olfactorius) (Fig. 3b).
Microglial activation [25] was also determined by co-
staining with two independent markers, P2Y12 (Fig. 3c) and
ionised calcium-binding adaptor molecule 1 (Iba1) (ESM Fig.
2). Diabetes was associated with an increased number of acti-
vated microglia (cells with thickened cell body, reduced num-
ber of processes and increased levels of reporter proteins, as
revealed by both blinded cell counting and unbiased integrated
density analysis). Diabetes-associated microglia activation was
not altered by losartan treatment (Fig. 3c) and the total number
of microglia remained unchanged as well (data not shown).
Analysis of glial fibrillary acidic protein (GFAP)-positive
astrocytes, however, revealed that GFAP levels (increased in
diabetic rats) were decreased by losartan (Fig. 3d), suggesting
that losartan treatment may directly or indirectly influence
astrocyte responses.
Since inflammatory responses in the brain are regulated via
bidirectional astrocyte–microglia interactions [26], we next
investigated how proinflammatory cytokine expression and
signalling were altered by diabetes and/or losartan. In fact,
increased expression of Il1a, Il6 and Tnf proinflammatory
cytokine mRNAs was detected in the hippocampus of diabetic
rats (Fig. 3f–h). This was associated with elevated NF-κB
protein levels (Fig. 3e), a key transcription factor involved in
IL-1 and TNF signalling [27]. Losartan treatment significantly
decreased NF-κB protein as well as Il1a, Il6 and Tnf mRNA
levels (Fig. 3e–h).
Losartan induces the production of both BDNF forms BDNF
is synthesised as proBDNF, which is subsequently cleaved
to mBDNF by intracellular (e.g. furin) or extracellular
(e.g. matrix metalloproteinases [MMPs], serine protease
plasmin) enzymes. Activation of the serine protease plas-
min requires proteolytic cleavage by tissue plasminogen
activator (TPA).
Diabetes led to reduced proBDNF and mBDNF levels and
this reduction was fully reversed by losartan treatment (Fig.
4a–c). Losartan also reversed diabetes-induced reduction in
furin levels (Fig. 4a, d). Losartan increased MMP3 protein
levels in diabetic rats vs control and vehicle-treated diabetic
rats (Fig. 4a, e). TPA levels were similar in all groups (Fig.
4a, f). These results suggest that losartan may facilitate BDNF
maturation in the hippocampi of diabetic rats.
BDNF, astrocytes (GFAP) and microglia (Iba1) were
visualised by triple immunohistochemistry staining in the den-
tate gyrus of the hippocampus to identify the cell types respon-
sible for BDNF production. The BDNF signal mostly
colocalised with astrocytes and, in accordance with decreased
BDNF protein levels, BDNF-positive astrocytes were less nu-
merous in diabetic rats (Fig. 4g).
Effect of losartan on hippocampal BDNF signalling ProBDNF
mediates neuronal apoptosis and decreases synaptic plasticity
via p75NTR. Levels of p75NTR and phosphorylated c-Jun N-ter-
minal kinase (JNK) proteins and pro-apoptotic Bax mRNA in
rat hippocampus were unaffected by diabetes and losartan treat-
ment (Fig. 5a–c, g). These results indicate that the proBDNF–
p75NTR pathway is not activated in the brains of diabetic rats.
mBDNF signalling mediates neuronal survival by binding
to and activating the TrkB receptor. The protein level of TrkB,
phosphorylated extracellular signal-regulated kinase (ERK)
and phosphorylated cAMP response element-binding protein
(CREB) and the mRNA level of anti-apoptotic Bcl2 decreased
in the hippocampus of diabetic rats (Fig. 5a, d–f, h). Losartan
treatment of the diabetic rats markedly elevated TrkB, p-ERK
and p-CREB protein levels as well as Bcl2mRNA expression
levels.
p-CREB immunohistochemistry staining in the hippo-
campal dentate gyrus confirmed western blot results by
showing that losartan treatment caused a marked upregu-
lation of p-CREB, while diabetes alone had no effect (Fig.
5i). p-CREB colocalised with neurons labelled with the
pan-neuronal marker protein gene product 9.5 (PGP 9.5)
but not with P2Y12-positive microglia or blood vessels
identified by tomato lectin, indicating that the changes
seen in p-CREB levels are due to altered activity of hip-
pocampal neurons (Fig. 5i, j). Thus, losartan interferes
with the detrimental effects of diabetes on BDNF signal-
ling in the brain, linking diabetes-induced depression with
neuroinflammation and the potential role of BDNF in this
experimental model.
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Fig. 2 Decreased cerebral perfusion of diabetic rats is unaltered by
losartan. (a) In control (non-diabetic) rats, vehicle-treated diabetic rats
(DM) and losartan-treated diabetic rats (DM+LOS), mean arterial
pressure was calculated. (b, c) Cerebral blood perfusion was measured
by SPECT–MRI based on [99mTc]HMPAOuptake. Representative images
from different sections of the whole brain. Colours represent the
magnitude of [99mTc]HMPAO uptake (green, purple and yellow
represent low, middle and high uptake, respectively) (b). Quantified
data revealed significantly decreased perfusion in all investigated brain
regions in DM and DM+LOS rats vs controls (c). (d, e) Cerebrovascular
activation was assessed by ICAM-1 immunostaining in coronal brain
sections of the dentate gyrus. Images are representative. Scale bar,
50 μm. (d) Integrated density of fluorescent images was determined by
using Image J and expressed as arbitrary units (e). (f, g) Protein levels of
p-eNOS (f) and endothelin-1 (g) in rat hippocampus were also evaluated
(fold change vs control, which was set as 1). Ponceau S total protein
staining was used as loading control (for a representative example of
Ponceau S-stained membranes, see ESM Fig. 3a). Data are presented as
mean ± SD (n = 4–5/group for imaging and n = 6–8/group for
inflammatory markers and histology). *p < 0.05 and **p < 0.01 vs
control rats. AU, arbitrary units; B. olfactorius, bulbus olfactorius
Fig. 3 Losartan mitigates proinflammatory cytokine responses in diabetic
rats. Neuroinflammation was assessed by various methods in control
(non-diabetic), vehicle-treated diabetic rats (DM) and losartan-treated di-
abetic rats (DM+LOS). (a, b) Microglia activation was measured indi-
rectly by SPECT–MRI based on [125I]CLINME uptake. (a)
Representative images from different sections of the whole brain.
Colours represent the magnitude of [125I]CLINME uptake (green, purple
and yellow represent low, middle and high uptake, respectively) (b)
Quantified data revealed significantly increased CLINME uptake in all
investigated brain regions in DM and DM+LOS rats. (c) Microglial acti-
vation was assessed by P2Y12 immunostaining. Arrowheads showing
P2Y12-positive microglia with thicker cell bodies and a partial withdraw-
al of processes (indicative of higher level of microglial activity). Scale
bar, 50 μm. Quantification was based on unbiased densitometric analysis
of P2Y12 signals in coronal brain sections of the dentate gyrus. (d) GFAP
immunostaining showing astrocyte responses to diabetes and losartan and
unbiased densitometric analysis showing reduced GFAP levels in coronal
brain sections of the dentate gyrus in the DM+LOS group compared with
the DM group (and control group). Scale bar, 100 μm. Due to technical
problems (inappropriate immunostaining), 5/7 rats were analysed in the
DM group. In (c) and (d), images are representative; integrated density of
fluorescent images was determined by using Image J software. (e–h)
Elevated protein level of NF-κB and mRNA expression of Il1a, Il6 and
Tnf were measured in the vehicle-treated diabetic rats; these effect was
abolished by losartan treatment. Data are presented as fold change vs
control, which was set as 1. Ponceau S total protein staining was used
as loading control (for a representative example of Ponceau S-stained
membranes, see ESM Fig. 3a.). Il1a, Il6 and TnfmRNA expression levels
were normalised to Rn18s expression. For Il6 and Tnf, due to technical
problems (inappropriate RNA isolation and PCR), 7/8 rats were analysed
in the vehicle-treated diabetic group. Data are presented as mean ± SD
(n = 4–6/group for imaging and n = 6–8/group elsewhere). *p < 0.05,
**p < 0.01 and ***p < 0.001 vs control rats; †p < 0.05 and †††p < 0.001
vs DM. AU, arbitrary units; B. olfactorius, bulbus olfactorius
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Discussion
The possible link between diabetes and depression is more
than 300 years old and is a re-emerging paradigm. ARBs are
a widely used clinical option for treatment of individuals with
various diabetes-associated complications. Furthermore, clini-
cal observations of the past decade unexpectedly revealed that
ARB-treated hypertensive individuals have a lower require-
ment for antidepressants [28, 29]. In addition, ARBs improved
interpersonal sensitivity and depression scores of individuals
with type 2 diabetes [15]. However, the molecular mechanisms
underlying these observations remain unexplored.
To test the hypothesis that ARBsmay exert an antidepressant
effect, we examined the effect of losartan in a rat STZ-induced
experimental diabetes model. We showed for the first time that
the depressive symptoms of diabetic rats can be effectively
minimised by losartan treatment and that the antidepressant ef-
fect of losartan is independent of blood glucose or body weight.
Cerebrovascular abnormalities are common in diabetes and
contribute to the development of depression [30, 31]. In
Fig. 4 BDNF production and localisation is normalised by losartan in
diabetic rats. (a–f) Representative blot (a) and quantification of protein
levels of proBDNF (b), mBDNF (c) and cleavage enzymes (d–f) in the
hippocampus of control (non-diabetic) rats, vehicle-treated diabetic rats
(DM) and losartan-treated diabetic rats (DM+LOS). Data are presented as
fold change vs control, which was set as 1. Ponceau S total protein stain-
ing was used as loading control (for a representative example of Ponceau
S-stained membranes, see ESM Fig. 3b). (g) Triple immunofluorescence
staining showing BDNF, GFAP-positive astrocytes and Iba1-positive mi-
croglia in the brain. Arrowheads in inserts indicate astrocytes with BDNF
immunopositivity. Representative images of coronal brain sections of the
dentate gyrus from three rats (representing each group) are shown. Scale
bar, 200μm.Data are presented asmean ± SD (n = 6–8/group). *p < 0.05,
**p < 0.01 and ***p < 0.001 vs control rats; †p < 0.05 and †††p < 0.001 vs
DM
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addition, RAAS is a central regulator of cerebral perfusion and
angiotensin II is the main effector causing local vasoconstric-
tion. Given the known associations between cerebrovascular
pathophysiology and depression (termed frequently as the
‘vascular hypothesis’ [32]), we first investigated whether
alterations in cerebral perfusion might be regulated by the
actions of losartan in diabetic rats. Impaired cerebral perfusion
was verified by a remarkable decline in cerebral relative
[99mTc]HMPAO uptake in diabetic rats and this decline was
not improved by losartan. We found that phosphorylated
Fig. 5 Losartan alters neuronal responses via mBDNF–TrkB signalling.
(a–f) Representative blot and protein levels of p75NTR (b), p-JNK (c),
TrkB (d), p-ERK (e) and p-CREB (f), in the hippocampus of control,
diabetic (DM) and losartan-treated diabetic (DM+LOS) rats. Ponceau S
total protein staining was used as loading control (for a representative
example of Ponceau S-stained membranes, see ESM Fig. 3b). (g, h)
mRNA expression levels of Bax (g) and Bcl2 (h) in the hippocampus.
mRNA expression of Bax and Bcl2 was normalised to Rn18s mRNA
expression. In (a–h), Data are expressed as fold change vs control, which
was set as 1. (i) Immunofluorescence images showing a marked upregu-
lation of p-CREB in the hippocampal dentate gyrus in response to
treatment with losartan. Integrated density of fluorescent images was
determined using Image J software. Densitometric analysis showed a
significant difference in p-CREB levels in DM+LOS compared with con-
trol and DM. No colocalisation of p-CREB with P2Y12-positive microg-
lia (green) or blood vessels identified by tomato lectin (blue) can be seen.
Scale bar, 100 μm. (j) p-CREB staining shows colocalisation with neu-
rons identified by the pan-neuronal marker protein gene product 9.5 (PGP
9.5). Scale bar, 50 μm. In (i) and (j), representative images of the dentate
gyrus are shown as captured in coronal brain sections. . Data are presented
as means ± SD (n = 6–8/group). *p < 0.05 and **p < 0.01 vs control rats;
†p < 0.05 and ††p < 0.01 vs DM. AU, arbitrary units
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eNOS levels remained unchanged while endothelin-1 levels
increased in diabetic brains, in parallel with elevated hippo-
campal ICAM-1 immunopositivity. These findings indicated
vascular activation, although the reduction in these variables
brought about by losartan did not reach statistical significance.
Thus, our results suggest that the beneficial effects of losartan
on behaviour may be independent of its direct vasoactive ac-
tions. This is in line with earlier observations showing miti-
gated neurological deficit by losartan without alterations in
cerebral blood flow in a murine model of type 2 diabetes [33].
Neuroinflammation is associated with both diabetes and
depression [34, 35], as indicated by the expression of proin-
flammatory mediators as well as microglia and astrocyte acti-
vation [36–38]. Increased [125I]CLINME-translocator protein
uptake in diabetic rats suggested microglial activation, which
was confirmed by immunohistochemistry, similar to that seen
in other studies after 6 weeks of STZ-induced diabetes in the
hippocampus [38]. Microglia and astrocyte activation was as-
sociated with the induction of an NF-κB-mediated inflamma-
tory response with elevated Il1a, Il6 and Tnf mRNA expres-
sion in diabetic rats, which was prevented by losartan. In line
with this, losartan treatment decreased the response of astro-
cytes, but not of microglia, suggesting that diabetes-induced
neuroinflammatory responses are modulated by losartan main-
ly via astrocytes. Previous studies in lipopolysaccharide-
induced inflammation and hypertensive models showed that
ARBs augment astrocyte and microglia activation [39, 40].
How mood disorders such as depression are influenced by
inflammatory processes is not well understood. The causal role
of proinflammatory mediators, namely IL-1 and TNF, has been
widely proposed [41]. For example, IL-1-mediated actions may
change neuronal network activity, the release of neurotransmit-
ters, autonomic nervous system and hypothalamic–pituitary–ad-
renal axis responses and levels of growth factors among others
[42, 43]. Recent studies indicate that neuroinflammatory process-
es may reduce BDNF expression [11, 12]. However, it remains
unclear whether inflammation-induced changes in BDNF levels
in the brain are associated with the formation of depression-
related behaviours and whether this can be reversed therapeuti-
cally. Here, for the first time, we demonstrated changes in both
forms of hippocampal BDNF in diabetes-associated depression.
We also showed earlier that proBDNF and mBDNF levels were
reduced in diabetes and were elevated by the antidepressant
fluvoxamine [44]. Our present results indicate that diabetes-
associated neuroinflammation, reduced BDNF levels and im-
paired BDNF signalling can be effectively reversed by an
ARB. While microglia sense and respond to diabetes-induced
effects, leading to long-lasting changes in their phenotype, this
was not affected by losartan. On the contrary, losartan decreased
astrocyte activation, reduced proinflammatory factors and re-
stored BDNF signalling, all of which may contribute to the alle-
viation of depressive symptoms. Literary data also strengthen our
point regarding the existence of this relationship. Diniz et al
infused a TrkB receptor antagonist into the ventral hippocampus
and prelimbic prefrontal cortex of rats and this prevented the
antidepressant effect of losartan [45]. Furthermore, they subject-
ed BDNF-haploinsufficient mice to FST and found that losartan
decreased immobility time in wild-type rats but not in the rats
with reduced BDNF levels. All these data support the direct link
between losartan, BDNF and depression.
It is important to identify the exact molecular pathways
through which impaired BDNF signalling may lead to the exac-
erbation of depressive symptoms in diabetes. Here, we found that
proapoptotic p75NTR–JNK–B cell lymphoma 2-associated X
protein (BAX) signalling is not activated, while the TrkB–
ERK–CREB pathway is substantially impaired after 7 weeks
of diabetes. However, the fact that despite losartan elevating
proBDNF levels, proapoptotic p75NTR–JNK–BAX signalling
was still suspended is rather interesting. It is plausible that
losartan activated extra- and intracellular cleavage enzymes
thereby promoting fast conversion of proBDNF to mBDNF.
We confirmed this hypothesis by detecting increased furin and
MMP3 levels in losartan-treated diabetic rats. Based on these
results we postulate that proBDNF immediately transforms to
mBDNF instead of activating its own receptor and downstream
signalling.
The present study is the first to investigate the effect of ARB
treatment on TrkB–ERK–CREB signalling in a model of diabe-
tes. TrkB, p-ERK and p-CREB levels were decreased in the
diabetic rat hippocampus, indicating that this pathway is re-
pressed. Our results are in accordance with previous studies
showing that TrkB and CREB activation is reduced in the hip-
pocampus in diabetes [46, 47]. Losartan treatment elevated the
TrkB, p-ERK and p-CREB levels, indicating that this pathway is
activated and promotes neuronal survival. Immunohistochemical
analysis also lent support to p-CREB levels being massively
increased by losartan in the diabetic hippocampus.
CREB is known to trigger the expression of several neuro-
protective proteins including B cell lymphoma 2 (BCL2) and
BDNF [48]. Tanaka observed that p-CREB-positive neurons
co-express BCL2 in the brain [49] and Ramirez et al showed that
neurotrophins upregulated BCL2 expression [50]. In line with
these observations, we show in the present study that losartan
increased Bcl2 expression and suggest that this may counteract
the detrimental effects of diabetes-associated inflammatory
changes in hippocampal neurons.
Based on these data we suggest that diabetes-induced neuro-
inflammation is, at least in part, responsible for decreased BDNF
levels, which facilitate the development of depression-like be-
haviour. Our data also indicate that the upregulation of BDNF
and p-CREB by ARBs may contribute to their neuroprotective
effects in diabetic individuals and could be selectively targeted to
alleviate some of the depressive symptoms associated with dia-
betes. Losartan also acts to restore the normal levels of BDNF via
facilitating the conversion of proBDNF to mBDNF. In conclu-
sion, our study suggests a novel potential of ARBs in diabetes-
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associated depression and may open up an additional therapeutic
option for diabetic individuals.
Acknowledgements Open access funding provided by Semmelweis
University (SE). The authors would like to thank the Nikon Microscopy
Center at IEM, Nikon Austria GmbH and Auro-Science Consulting Ltd.
for technical support for fluorescence imaging. The authors acknowledge
E. Mikics (Department of Behavioral Neurobiology, Institute of
Experimental Medicine, Budapest, Hungary) for critical discussion of
behaviour test data. We also thank D. Mathe (Department of Biophysics
and Radiation Biology, Semmelweis University, Budapest, Hungary), D.
Szollosi (Department of Biophysics and Radiation Biology, Semmelweis
University, Budapest, Hungary) and CROmed Ltd. (Budapest, Hungary)
for providing SPECT quantification methodologies. The authors specifi-
cally thank A. Molnar (MTA-SE Lendület Diabetes Research Group,
Budapest, Hungary) and I. Kovacs (Department of Ophthalmology,
Semmelweis University, Budapest, Hungary) for the statistical evaluation
and E. Szkibinszkij (MTA-SE Lendület Diabetes Research Group,
Budapest, Hungary) for technical assessment.
Data availability Data are available on request from the authors.
Funding This work was supported by OTKA-K112629 -FK124491,
NN-11460, VKE-2017-00006, EEMOFAKT-2017, the ‘Momentum’
Program of the Hungarian Academy of Sciences LP008/2017, ERC-
CoG 724994 and European Union Seventh Framework Programme
FP7/2007-2013 under grant agreement no. 305311 (INSERT). This re-
search received no specific grant from any funding agency in the public,
commercial or not-for-profit sectors.
Duality of interest The authors declare that there is no duality of interest
associated with this manuscript.
Contribution statement LLmade substantial contributions to conception
and design, acquisition of data, analysis and interpretation of data,
drafting and revising the article critically for important intellectual con-
tent. AF and AD made substantial contributions to conception, drafting
and revising the article critically for important intellectual content. DBB,
JH, AHmade substantial contributions to acquisition of data, analysis and
interpretation of data, drafting and revising the article critically for impor-
tant intellectual content. NL, AB, TF, KS made substantial contributions
to acquisition of data, analysis and interpretation of data and revising the
article critically for important intellectual content. AJS made substantial
contributions to conception and revising it critically for important intel-
lectual content. All authors gave final approval of the version to be pub-
lished. AF is the guarantor of this work and, as such, had full access to all
the data in the study and is responsible for the integrity of the work as a
whole.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Badescu SV, Tataru C, Kobylinska L et al (2016) The association
between diabetes mellitus and depression. J Med Life 9(2):120–125
2. de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ
(2001) Association of depression and diabetes complications: a
meta-analysis. Psychosom Med 63(4):619–630. https://doi.org/10.
1097/00006842-200107000-00015
3. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ (2001) The
prevalence of comorbid depression in adults with diabetes: a meta-
analysis. Diabetes Care 24(6):1069–1078. https://doi.org/10.2337/
diacare.24.6.1069
4. Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and dia-
betes. J Clin Invest 115(5):1111–1119. https://doi.org/10.1172/
JCI25102
5. Korczak DJ, Pereira S, Koulajian K, Matejcek A, Giacca A (2011)
Type 1 diabetes mellitus and major depressive disorder: evidence
for a biological link. Diabetologia 54(10):2483–2493. https://doi.
org/10.1007/s00125-011-2240-3
6. Castren E, Voikar V, Rantamaki T (2007) Role of neurotrophic
factors in depression. Curr Opin Pharmacol 7(1):18–21. https://
doi.org/10.1016/j.coph.2006.08.009
7. Pandey GN, Ren X, Rizavi HS, Conley RR, Roberts RC, Dwivedi
Y (2008) Brain-derived neurotrophic factor and tyrosine kinase B
receptor signalling in post-mortem brain of teenage suicide victims.
Int J Neuropsychopharmacol 11(08):1047–1061. https://doi.org/10.
1017/S1461145708009000
8. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT
(2001) Increased hippocampal BDNF immunoreactivity in subjects
treated with antidepressant medication. Biol Psychiatry 50(4):260–
265. https://doi.org/10.1016/S0006-3223(01)01083-6
9. Lu B, Pang PT, Woo NH (2005) The yin and yang of neurotrophin
action. Nat Rev Neurosci 6(8):603–614. https://doi.org/10.1038/
nrn1726
10. Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R
(2014) Brain-derived neurotrophic factor: a bridge between inflam-
mation and neuroplasticity. Front Cell Neurosci 8:430
11. Lapchak PA, Araujo DM, Hefti F (1993) Systemic interleukin-1β
decreases brain-derived neurotrophic factor messenger RNA ex-
pression in the rat hippocampal formation. Neuroscience 53(2):
297–301. https://doi.org/10.1016/0306-4522(93)90196-M
12. Guan Z, Fang J (2006) Peripheral immune activation by lipopoly-
saccharide decreases neurotrophins in the cortex and hippocampus
in rats. Brain Behav Immun 20(1):64–71. https://doi.org/10.1016/j.
bbi.2005.04.005
13. American Diabetes Association (2018) 10. Microvascular compli-
cations and foot care: standards of medical care in diabetes 2018.
Diabetes Care 41(Suppl 1):S105–S118. https://doi.org/10.2337/
dc18-S010
14. Ahola AJ, Harjutsalo V, Forsblom C, Groop PH (2014) Renin-
angiotensin-aldosterone-blockade is associated with decreased use
of antidepressant therapy in patients with type 1 diabetes and dia-
betic nephropathy. Acta Diabetol 51(4):529–533. https://doi.org/10.
1007/s00592-013-0547-x
15. Pavlatou MG, Mastorakos G, Lekakis I et al (2008) Chronic ad-
ministration of an angiotensin II receptor antagonist resets the
hypothalamic-pituitary-adrenal (HPA) axis and improves the affect
of patients with diabetes mellitus type 2: preliminary results. Stress
11(1):62–72. https://doi.org/10.1080/10253890701476621
16. Paul M, PoyanMehr A, Kreutz R (2006) Physiology of local renin-
angiotensin systems. Physiol Rev 86(3):747–803. https://doi.org/
10.1152/physrev.00036.2005
17. Wang J, Ho L, Chen L et al (2007) Valsartan lowers brain beta-
amyloid protein levels and improves spatial learning in a mouse
model of Alzheimer disease. J Clin Invest 117(11):3393–3402.
https://doi.org/10.1172/JCI31547
18. Reardon KA, Mendelsohn FA, Chai SY, Horne MK (2000) The
angiotensin converting enzyme (ACE) inhibitor, perindopril, mod-
ifies the clinical features of Parkinson’s disease. Aust NZ J Med
30(1):48–53. https://doi.org/10.1111/j.1445-5994.2000.tb01054.x
19. Isingrini E, Desmidt T, Belzung C, Camus V (2009) Endothelial
dysfunction: a potential therapeutic target for geriatric depression
1512 Diabetologia (2019) 62:1501–1513
and brain amyloid deposition in Alzheimer s disease? Curr Opin
Investig Drugs 10:46–55
20. Gellai R, Hodrea J, Lenart L et al (2016) Role of O-linked N-
acetylglucosamine modification in diabetic nephropathy. Am J
Physiol Renal Physiol 311(6):F1172–F1181. https://doi.org/10.
1152/ajprenal.00545.2015
21. De Pablo JM, Parra A, Segovia S, Guillamon A (1989) Learned
immobility explains the behavior of rats in the forced swimming
test. Physiol Behav 46(2):229–237. https://doi.org/10.1016/0031-
9384(89)90261-8
22. Lass P, Knudsen GM, Pedersen EV, Barry DI (1989) Impaired beta-
adrenergic mediated cerebral blood flow response in streptozotocin
diabetic rats. Pharmacol Toxicol 65(4):318–320. https://doi.org/10.
1111/j.1600-0773.1989.tb01181.x
23. Suzuki C, Kimura S, Kosugi M, Magata Y (2017) Quantitation of
rat cerebral blood flow using 99mTc-HMPAO. Nucl Med Biol 47:
19–22. https://doi.org/10.1016/j.nucmedbio.2016.12.006
24. Denes A, Drake C, Stordy J et al (2012) Interleukin-1 mediates
neuroinflammatory changes associated with diet-induced athero-
sclerosis. J Am Heart Assoc 1:e002006
25. Haynes SE, Hollopeter G, Yang G et al (2006) The P2Y12 receptor
regulates microglial activation by extracellular nucleotides. Nat
Neurosci 9(12):1512–1519. https://doi.org/10.1038/nn1805
26. Carson MJ, Thrash JC, Walter B (2006) The cellular response in
neuroinflammation: the role of leukocytes, microglia and astrocytes
in neuronal death and survival. Clin Neurosci Res 6(5):237–245.
https://doi.org/10.1016/j.cnr.2006.09.004
27. Lawrence T (2009) The nuclear factor NF-kappaB pathway in in-
flammation. Cold Spring Harb Perspect Biol 1:a001651
28. Braszko JJ, Karwowska-Polecka W, Halicka D, Gard PR (2003)
Captopril and enalapril improve cognition and depressed mood in hy-
pertensive patients. J Basic Clin Physiol Pharmacol 14(4):323–343
29. Nasr SJ, Crayton JW, Agarwal B, Wendt B, Kora R (2011) Lower
frequency of antidepressant use in patients on renin-angiotensin-
aldosterone system modifying medications. Cell Mol Neurobiol
31(4):615–618. https://doi.org/10.1007/s10571-011-9656-7
30. Kales HC, Maixner DF, Mellow AM (2005) Cerebrovascular dis-
ease and late-life depression. Am J Geriatr Psychiatry 13(2):88–98.
https://doi.org/10.1097/00019442-200502000-00002
31. Cooper ME, Gilbert RE, Jerums G (1997) Diabetic vascular com-
plications. Clin Exp Pharmacol Physiol 24(9-10):770–775. https://
doi.org/10.1111/j.1440-1681.1997.tb02130.x
32. Sneed JR, Culang-Reinlieb ME (2011) The vascular depression
hypothesis: an update. Am J Geriatr Psychiatry 19(2):99–103.
https://doi.org/10.1097/JGP.0b013e318202fc8a
33. Iwanami J, Mogi M, Tsukuda K et al (2010) Low dose of
telmisartan prevents ischemic brain damage with peroxisome
proliferator-activated receptor-gamma activation in diabetic mice.
J Hypertens 28(8):1730–1737. https://doi.org/10.1097/HJH.
0b013e32833a551a
34. Stuart MJ, Baune BT (2012) Depression and type 2 diabetes: in-
flammatory mechanisms of a psychoneuroendocrine co-morbidity.
Neurosci Biobehav Rev 36(1):658–676. https://doi.org/10.1016/j.
neubiorev.2011.10.001
35. Vargas R, Rincon J, Pedreanez A et al (2012) Role of angiotensin II
in the brain inflammatory events during experimental diabetes in
rats. Brain Res 1453:64–76. https://doi.org/10.1016/j.brainres.
2012.03.021
36. Jensen CJ, Massie A, De Keyser J (2013) Immune players in the
CNS: the astrocyte. J NeuroImmune Pharmacol 8(4):824–839.
https://doi.org/10.1007/s11481-013-9480-6
37. Cerbai F, Lana D, Nosi D et al (2012) The neuron-astrocyte-
microglia triad in normal brain ageing and in a model of neuroin-
flammation in the rat hippocampus. PLoS One 7(9):e45250. https://
doi.org/10.1371/journal.pone.0045250
38. Nagayach A, Patro N, Patro I (2014) Astrocytic and microglial
response in experimentally induced diabetic rat brain. Metab
Brain Dis 29(3):747–761. https://doi.org/10.1007/s11011-014-
9562-z
39. Bhat SA, Goel R, Shukla S, Shukla R, Hanif K (2018) Angiotensin
receptor blockade by inhibiting glial activation promotes hippo-
campal neurogenesis via activation of Wnt/β-catenin signaling in
hypertension. Mol Neurobiol 55(6):5282–5298. https://doi.org/10.
1007/s12035-017-0754-5
40. Bhat SA, Goel R, Shukla R, Hanif K (2016) Angiotensin receptor
blockade modulates NFκB and STAT3 signaling and inhibits glial
activation and neuroinflammation better than angiotensin-
converting enzyme inhibition. Mol Neurobiol 53(10):6950–6967.
https://doi.org/10.1007/s12035-015-9584-5
41. Felger JC, Lotrich FE (2013) Inflammatory cytokines in depres-
sion: neurobiological mechanisms and therapeutic implications.
Neuroscience 246:199–229. https://doi.org/10.1016/j .
neuroscience.2013.04.060
42. Song C (2002) The effect of thymectomy and IL-1 on memory:
implications for the relationship between immunity and depression.
Brain Behav Immun 16(5):557–568. https://doi.org/10.1016/
S0889-1591(02)00012-0
43. Takahashi H, Nishimura M, Sakamoto M, Ikegaki I, Nakanishi T,
Yoshimura M (1992) Effects of interleukin-1β on blood pressure,
sympathetic nerve activity, and pituitary endocrine functions in
anesthetized rats. Am J Hypertens 5(4 Pt 1):224–229. https://doi.
org/10.1093/ajh/5.4.224
44. Lenart L, Hodrea J, Hosszu A et al (2016) The role of sigma-1
receptor and brain-derived neurotrophic factor in the development
of diabetes and comorbid depression in streptozotocin-induced di-
abetic rats. Psychopharmacology 233(7):1269–1278. https://doi.
org/10.1007/s00213-016-4209-x
45. Diniz C, Casarotto PC, Fred SM, Biojone C, Castren E, Joca SRL
(2018) Antidepressant-like effect of losartan involves TRKB
transactivation from angiotensin receptor type 2 (AGTR2) and re-
cruitment of FYN. Neuropharmacology 135:163–171. https://doi.
org/10.1016/j.neuropharm.2018.03.011
46. Yang Y, Gao L (2017) Celecoxib alleviates memory deficits by
downregulation of COX-2 expression and upregulation of the
BDNF-TrkB signaling pathway in a diabetic rat model. J Mol
Neurosci 62(2):188–198. https://doi.org/10.1007/s12031-017-
0922-0
47. Xiang Q, Zhang J, Li CY et al (2015) Insulin resistance-induced
hyperglycemia decreased the activation of Akt/CREB in hippocam-
pus neurons: molecular evidence for mechanism of diabetes-
induced cognitive dysfunction. Neuropeptides 54:9–15. https://
doi.org/10.1016/j.npep.2015.08.009
48. Kitagawa K (2007) CREB and cAMP response element-mediated
gene expression in the ischemic brain. FEBS J 274(13):3210–3217.
https://doi.org/10.1111/j.1742-4658.2007.05890.x
49. Tanaka K (2001) Alteration of second messengers during acute
cerebral ischemia - adenylate cyclase, cyclic AMP-dependent pro-
tein kinase, and cyclic AMP response element binding protein. Prog
Neurobiol 65(2):173–207. https://doi.org/10.1016/S0301-0082(01)
00002-8
50. Ramirez SH, Sanchez JF, Dimitri CA, Gelbard HA, Dewhurst S,
Maggirwar SB (2001) Neurotrophins prevent HIV Tat-induced
neuronal apoptosis via a nuclear factor-κB (NF-κB)-dependent
mechanism. J Neurochem 78(4):874–889. https://doi.org/10.1046/
j.1471-4159.2001.00467.x
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Diabetologia (2019) 62:1501–1513 1513
